These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2701308)

  • 21. Rifampin-induced methadone withdrawal in AIDS.
    Holmes VF
    J Clin Psychopharmacol; 1990 Dec; 10(6):443-4. PubMed ID: 2286719
    [No Abstract]   [Full Text] [Related]  

  • 22. Initial methadone dose in treating opiate addiction.
    Wang RI; Kochar C; Hasegawa AT; Roh BL
    Int J Addict; 1982 Feb; 17(2):357-63. PubMed ID: 7076369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance.
    Calsyn DA; Malcy JA; Saxon AJ
    J Subst Abuse Treat; 2006 Mar; 30(2):159-63. PubMed ID: 16490679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy.
    Charney DS; Riordan CE; Kleber HD; Murburg M; Braverman P; Sternberg DE; Heninger GR; Redmond DE
    Arch Gen Psychiatry; 1982 Nov; 39(11):1327-32. PubMed ID: 7138234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of clonidine in opiate withdrawal: a study of 100 patients.
    Gold MS; Kleber HD
    Prog Clin Biol Res; 1981; 71():299-306. PubMed ID: 6276899
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single dose of methadone.
    Wright C; Bigelow GE; Stitzer ML; Liebson IA
    Drug Alcohol Depend; 1991 Mar; 27(2):139-48. PubMed ID: 1647293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.
    Jones HE; Johnson RE; Jasinski DR; Milio L
    Drug Alcohol Depend; 2005 Apr; 78(1):33-8. PubMed ID: 15769555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of symptom complaints in methadone maintenance patients.
    Dyer KR; White JM
    Addiction; 1997 Nov; 92(11):1445-55. PubMed ID: 9519488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
    Mintzer MZ; Correia CJ; Strain EC
    Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress report from the NIDA Addiction Research Center, Baltimore, Maryland.
    Jasinski DR; Boren JJ; Henningfield JE; Johnson RE; Lange WR; Lukas SE
    NIDA Res Monogr; 1984 Mar; 49():69-76. PubMed ID: 6148697
    [No Abstract]   [Full Text] [Related]  

  • 33. Time course of repeated naloxone challenge after single morphine doses in humans.
    Heishman SJ; Stitzer ML
    NIDA Res Monogr; 1989; 95():385-6. PubMed ID: 2641004
    [No Abstract]   [Full Text] [Related]  

  • 34. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
    Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
    Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome.
    Janiri L; Martinotti G; Tonioni F; Ghelardini C; Nicolai R; Galeotti N; Mosconi L; Calvani M; Bartolini A; Iannoni E
    Clin Neuropharmacol; 2009; 32(1):35-40. PubMed ID: 18978503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
    Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
    Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1987; 76():157-61. PubMed ID: 2449617
    [No Abstract]   [Full Text] [Related]  

  • 39. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
    Clarke S; Mulcahy F; Bergin C; Reynolds H; Boyle N; Barry M; Back DJ
    Clin Infect Dis; 2002 Apr; 34(8):1143-5. PubMed ID: 11915005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.